We’re the leading resource for West Virginians affected by bleeding disorders. You can count on WVNHF to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.
MASAC's latest set of recommendations cover the use and management of emicizumab, the latest products licensed to treat bleeding disorders, integrating the CDC's opioid prescribing guidelines into bleeding disorders care, and bleeding prophylaxis for patients undergoing gastrointestinal endoscopies.
On March 20th, NHF’s President and CEO answered your questions about how COVID-19 affects our community.
Information and techniques you and your family can use to stay healthy during the COVID-19 pandemic.
Do you have questions regarding insurance coverage in light of the COVID-19 pandemic? We're here to help.
The halted trials were investigating concizumab prophylaxis treatment in hemophilia A and B patients regardless of inhibitor status.
Subscribe to Our Newsletter
Fill in the fields below to receive our email newsletter.